Ladenburg analyst Jeffrey Cohen believes that an 8-K filing made by ChromaDex (CDXC) on December 4 “may have been misconstrued by the market.” The Dartmouth-owned patents had been previously ruled invalid, essentially closing and concluding the arrangement between the two parties, and the agreement ensures that the company will not owe any royalties to Dartmouth, explains the analyst, who adds that the 8-K has no impact on the company’s intellectual property position, which the firm believes is “extremely strong.” Ladenburg has a Buy rating and $6.80 price target on ChromaDex shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDXC: